U.S. Life Sciences Stock News

Leonardo DRS (DRS) just closed out FY 2025 with fourth quarter revenue of US$1.1b and basic EPS of US$0.39, capped by trailing twelve month revenue of US$3.6b and EPS of US$1.05 as profit growth outpaced the company’s five year trend. The business has seen revenue move from US$981 million in Q4 2024 to US$1.1b in Q4 2025, while quarterly EPS shifted from US$0.34 to US$0.39 over the same period, against a backdrop of 30.5% earnings growth over the last year and a net margin that improved from...

Paymentus Holdings (PAY) has wrapped up FY 2025 with Q4 revenue of US$330.5 million and basic EPS of US$0.16, while trailing twelve month revenue reached US$1.2 billion and EPS came in at US$0.53. The company has seen quarterly revenue move from US$257.9 million in Q4 2024 to US$330.5 million in Q4 2025, with basic EPS over that span ranging from US$0.11 to US$0.16, and trailing net profit margin running at 5.6%. For investors, that combination of higher revenue scale, expanding EPS and a...

If you are wondering whether CMS Energy's current share price offers fair value or a potential opportunity, looking beyond the headline number can help you build a clearer view. With CMS Energy recently closing at US$76.78 and returns of 1.0% over 7 days, 8.6% over 30 days, 9.0% year to date, 8.2% over 1 year, 43.2% over 3 years, and 63.0% over 5 years, many investors are reassessing what they are paying for the stock today. Recent coverage has focused on CMS Energy as a regulated utilities...

Digital Turbine, Inc. recently appointed Ben John, a veteran ad-tech and AI leader formerly at Microsoft and Xandr, as Chief Technology Officer to oversee global engineering, product architecture, data-centric scaling, and AI-driven development. This move comes alongside strong year-over-year revenue and EBITDA growth linked to international expansion and AI integration, highlighting management’s focus on turning technical capabilities into operational efficiency and business outcomes. We’ll...

Hims & Hers Health (HIMS) has capped FY 2025 with fourth quarter revenue of US$617.8 million and basic EPS of US$0.09, rounding out a year in which its trailing twelve month revenue reached about US$2.3 billion and basic EPS came in at roughly US$0.57. Over recent periods the company has seen revenue move from US$481.1 million in Q4 2024 to US$617.8 million in Q4 2025, while quarterly basic EPS shifted from US$0.12 a year ago to US$0.09 most recently. This has set up a results season where...

Ally Financial (NYSE:ALLY) approved a new $2 billion open-ended share repurchase program. The buyback plan follows a recent refresh of the company’s priorities and capital approach. The program adds a new capital return lever alongside existing efforts to refine the business mix. Ally Financial enters this move with its shares at $40.51 and a mixed performance profile, including a 14.7% gain over the past year and a 49.7% return over three years. Returns over the past month and year to date...

If you are wondering whether DuPont de Nemours shares still offer value at around US$51.07, it helps to step back and look at what the current price might be implying about the business. The stock has returned 0.4% over the last 7 days, 15.7% over the past month, 25.0% year to date and 52.3% over the past year, with longer term returns of 76.8% over 3 years and 83.4% over 5 years. Recent news around DuPont has focused on the company's portfolio positioning and its place in the broader...

Domino’s Pizza (DPZ) has wrapped up FY 2025 with fourth quarter revenue of US$1.5b and basic EPS of US$5.35, setting the tone for a year where trailing twelve month revenue came in at about US$4.9b and EPS reached US$17.69. Over recent quarters, revenue has ranged from US$1.1b to US$1.5b while quarterly EPS has moved between roughly US$3.84 and US$5.35. This gives investors a clear read on how sales and earnings are tracking into the current share price of US$414.20. With trailing net margins...

In February 2026, Lazard, Inc. added John Koski and Rob Lowe as Managing Directors in its New York Healthcare Group, bringing experience across payors, providers, distributors, and healthcare–technology transactions from roles at Allen & Co. and Citi. Around the same time, Lazard reported quarterly results with revenue growth but pressure on margins and earnings, prompting investors to weigh expansion efforts against profitability trends and insider share sales. Next, we’ll examine how...

If you are wondering whether PACCAR's current share price reflects its underlying worth, this article walks through the key numbers that matter for valuation. PACCAR's stock recently closed at US$126.25, with returns of 3.5% over the past 30 days, 13.2% year to date, and 21.5% over the last year. The 7 day return sits at a 0.2% decline and the 3 year and 5 year returns are 95.3% and 142.0% respectively. Recent news around PACCAR has focused on its position as a major commercial vehicle...

Keurig Dr Pepper (KDP) has wrapped up FY 2025 with fourth quarter revenue of US$4.5 billion and basic EPS of US$0.26, setting the tone for how investors assess the full year. The company has seen quarterly revenue move from US$4.1 billion in Q4 2024 to US$4.5 billion in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 to EPS of US$0.26 over the same period, against a trailing twelve month EPS of US$1.53. With trailing net margin at 12.5% and earnings growth highlighted over the...

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...

DigitalOcean Holdings FY 2025 Earnings Snapshot DigitalOcean Holdings (DOCN) has wrapped up FY 2025 with Q4 revenue of US$242.4 million and basic EPS of US$0.28, capping off a year in which trailing twelve month revenue reached US$901.4 million and EPS came in at US$2.83. The company has seen revenue move from US$780.6 million to US$901.4 million on a trailing twelve month basis, while EPS shifted from US$0.92 to US$2.83, with reported earnings growth helped by a very large year over year...

If you are wondering whether Bruker is priced attractively right now, you are not alone, especially with sentiment around the stock shifting recently. The share price closed at US$39.77, with a 4.3% gain over the last 7 days, set against returns of a 21.0% decline over 30 days, a 17.3% decline year to date, and a 21.6% decline over 1 year, as well as 41.7% and 35.1% declines over 3 and 5 years respectively. These mixed shorter term and longer term returns have put more attention on what...

If you are wondering whether TG Therapeutics at around US$30.51 is priced attractively or already baking in a lot of optimism, you are in the right place. The stock has returned 5.0% over the last 7 days, is down 2.2% over 30 days, and shows mixed longer term results with a 4.2% return year to date, 4.5% over 1 year, 90.4% over 3 years, and a 32.0% decline over 5 years. These moves sit against a backdrop of ongoing interest in TG Therapeutics as a biotechnology name, with investors watching...

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies. This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers. Twist...

If you are trying to work out whether Caris Life Sciences at around US$18.20 is a bargain or a value trap, you are in the right place. The stock has been under pressure recently, with a 12.5% decline over the last 7 days, a 27.2% decline over the last 30 days, and a 32.5% decline year to date. Recent attention around Caris Life Sciences has focused on its position in the pharmaceuticals and biotech space and how investors are reassessing risk in the sector. This backdrop helps explain why...

If you are wondering whether Danaos is still good value after its recent run, you are in the right place. This article focuses squarely on what you are paying for each dollar of the business. The stock last closed at US$111.57, with returns of 4.0% over 7 days, 10.8% over 30 days, 17.1% year to date, 41.5% over 1 year and 116.4% over 3 years. These figures naturally raise questions about how much upside or risk is now priced in. Recent coverage of Danaos has highlighted its role in the...

Concentra Group Holdings Parent: Recent Moves In Context With no single headline event driving attention to Concentra Group Holdings Parent (CON), investors are focusing on how its recent share performance and financial profile fit into the occupational health services story. See our latest analysis for Concentra Group Holdings Parent. At a share price of $23.41, Concentra Group Holdings Parent has paired a 1 month share price return of 8.63% with a year to date share price return of 20.61%...

If you are wondering whether Regal Rexnord’s current share price really reflects what the business is worth, you are not alone. This article is built to help you assess that question clearly. With the stock at US$223.69 and returns of 2.1% over 7 days, 43.3% over 30 days, 53.1% year to date and 69.7% over 1 year, many investors are asking what is already priced in and what might still be on the table in terms of risk and reward. These moves sit against a backdrop where Regal Rexnord...

If you are wondering whether Knowles is fairly priced at around US$28.07 per share, you are not alone. This article will focus squarely on what that means for value minded investors. The stock has posted returns of 3.4% over the past week, 17.3% over the last 30 days, 27.9% year to date, 62.5% over 1 year and 65.3% over 3 years, with a 5 year return of 32.8%. This naturally raises questions about what is already reflected in the price. Recent coverage around Knowles has centered on its...

Knife River (KNF) just reported fourth quarter and full year 2025 results, with revenue and net income above the prior year’s quarter, and issued 2026 revenue guidance in the US$3.3b to US$3.5b range. See our latest analysis for Knife River. The latest earnings and 2026 guidance arrived after a strong recent run in the share price, with a 30 day share price return of 21.07% and a 90 day share price return of 20.14%, even though the 1 year total shareholder return is a 4.59% decline, which...

Analysts are flagging anticipated revenue declines for Fortive, citing softer demand and slower organic growth expectations. This shift in sentiment follows previously solid quarterly results and points to a possible inflection in the company’s operational outlook. The change comes as investors reassess Fortive’s near term growth profile beyond recent share price moves. For investors watching Fortive, ticker NYSE:FTV, the backdrop is a mix of steady share performance and growing questions...

Array Digital Infrastructure (NYSE:AD) has completed a transformation by selling its wireless operations and related spectrum assets. The company transferred spectrum holdings to major carriers, including T-Mobile and AT&T, and repositioned itself as a focused tower operator. Array Digital Infrastructure secured new long term Master License Agreements with top telecom companies for tower usage. The company distributed special dividends and outlined plans to invest further in its...